Published in J Clin Gastroenterol on October 24, 2016
Recent advances in the management of variceal bleeding. Gastroenterol Rep (Oxf) (2017) 0.76
Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology (2007) 9.44
Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med (2010) 8.40
Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med (2010) 5.37
Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol (2005) 3.68
Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology (2003) 3.19
Early administration of vapreotide for variceal bleeding in patients with cirrhosis. N Engl J Med (2001) 2.25
Risk of Bacterial Infection in Patients With Cirrhosis and Acute Variceal Hemorrhage, Based on Child-Pugh Class, and Effects of Antibiotics. Clin Gastroenterol Hepatol (2014) 2.05
A MELD-based model to determine risk of mortality among patients with acute variceal bleeding. Gastroenterology (2013) 1.77
Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. J Hepatol (2007) 1.60
Predictors of early re-bleeding and mortality after acute variceal haemorrhage in patients with cirrhosis. Gut (2008) 1.56
Predicting early mortality after acute variceal hemorrhage based on classification and regression tree analysis. Clin Gastroenterol Hepatol (2009) 1.24
Effectiveness of combined pharmacologic and ligation therapy in high-risk patients with acute esophageal variceal bleeding. Am J Gastroenterol (2011) 1.17
The effectiveness of current acute variceal bleed treatments in unselected cirrhotic patients: refining short-term prognosis and risk factors. Am J Gastroenterol (2012) 1.16
Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 29.57
Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30
Rifaximin treatment in hepatic encephalopathy. N Engl J Med (2010) 9.60
Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology (2007) 9.44
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25
Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med (2005) 6.31
Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol (2005) 6.22
The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology (2012) 5.47
Vascular disorders of the liver. Hepatology (2009) 5.38
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med (2014) 5.29
Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med (2007) 5.13
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med (2014) 4.90
Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology (2003) 4.69
Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology (2007) 4.09
Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med (2008) 4.07
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology (2015) 3.96
Acute-on chronic liver failure. J Hepatol (2012) 3.74
Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology (2008) 3.68
A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology (2007) 3.65
The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol (2013) 3.51
Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology (2002) 3.50
The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology (2009) 3.48
Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology (2004) 3.45
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med (2014) 3.40
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA (2011) 3.37
Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T. Radiology (2009) 3.31
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30
Inhaled NO accelerates restoration of liver function in adults following orthotopic liver transplantation. J Clin Invest (2007) 3.22
A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology (2003) 3.09
Bacterial translocation (BT) in cirrhosis. Hepatology (2005) 3.07
Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology (2007) 3.06
An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med (2014) 3.04
Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology (2011) 2.97
The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. Hepatology (2007) 2.94
Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology (2005) 2.91
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis. Gastroenterology (2013) 2.82
Sepsis-induced cholestasis. Hepatology (2007) 2.80
Improvement in survival associated with adult-to-adult living donor liver transplantation. Gastroenterology (2007) 2.72
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology (2013) 2.70
A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology (2008) 2.69
Clinical risk factors for portopulmonary hypertension. Hepatology (2008) 2.62
Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis (2008) 2.47
Alcohol and smoking as risk factors in an epidemiology study of patients with chronic pancreatitis. Clin Gastroenterol Hepatol (2010) 2.46
Prediction of esophageal varices in patients with cirrhosis. J Clin Gastroenterol (2002) 2.45
Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (2009) 2.42
Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol (2009) 2.42
Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis (2012) 2.41
Hemostasis and thrombosis in patients with liver disease: the ups and downs. J Hepatol (2010) 2.41
Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology (2009) 2.40
The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. Am J Gastroenterol (2011) 2.37
Pulmonary vascular complications of liver disease. Am J Respir Crit Care Med (2012) 2.33
Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver Int (2010) 2.32
Outcomes of living donor liver transplantation for acute liver failure: the adult-to-adult living donor liver transplantation cohort study. Liver Transpl (2008) 2.30
Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology (2002) 2.25
MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology (2009) 2.23
Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol (2009) 2.22
An explicit quality indicator set for measurement of quality of care in patients with cirrhosis. Clin Gastroenterol Hepatol (2010) 2.18
Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol (2003) 2.18
Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials (2008) 2.17
Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol (2010) 2.16
Spectrum of neurocognitive impairment in cirrhosis: Implications for the assessment of hepatic encephalopathy. Hepatology (2009) 2.16
Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology (2014) 2.14
Cost-effectiveness of screening for hepatopulmonary syndrome in liver transplant candidates. Liver Transpl (2007) 2.13
Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology (2008) 2.10
Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int (2008) 2.10
Nurse observation during colonoscopy increases polyp detection: a randomized prospective study. Am J Gastroenterol (2013) 2.08
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology (2014) 2.04
Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology (2009) 2.02
Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology (2012) 2.01
Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. Am J Clin Nutr (2007) 1.99
Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology (2002) 1.98
Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab (2012) 1.97
Nitric oxide synthase generates nitric oxide locally to regulate compartmentalized protein S-nitrosylation and protein trafficking. Proc Natl Acad Sci U S A (2006) 1.97
Clostridium difficile is associated with poor outcomes in patients with cirrhosis: A national and tertiary center perspective. Am J Gastroenterol (2009) 1.93
The Stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy. Hepatology (2013) 1.92
Esophageal capsule endoscopy for screening and surveillance of esophageal varices in patients with portal hypertension. Hepatology (2008) 1.91
Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology (2007) 1.90
Donor morbidity after living donation for liver transplantation. Gastroenterology (2008) 1.90
Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology (2014) 1.89
The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. J Clin Oncol (2003) 1.88
Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Am J Gastroenterol (2007) 1.87
Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis. Hepatology (2012) 1.86
MELD-XI: a rational approach to "sickest first" liver transplantation in cirrhotic patients requiring anticoagulant therapy. Liver Transpl (2007) 1.86
Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography. J Hepatol (2011) 1.85
Racial disparities in the management of hospitalized patients with cirrhosis and complications of portal hypertension: a national study. Hepatology (2007) 1.82